Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)

Launched by TONGJI HOSPITAL · Jun 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called telitacicept for patients with systemic lupus erythematosus (SLE), an autoimmune disease where the immune system mistakenly attacks healthy tissues. Telitacicept works by blocking certain signals that help the immune system's B cells develop and activate, which may reduce the symptoms of SLE. The trial aims to find out how safe and effective telitacicept is, as well as how well patients stick to the treatment plan.

To participate in the trial, individuals must be between 18 and 70 years old and have been diagnosed with SLE according to specific criteria. However, those with other autoimmune diseases, active infections, or who are taking other biologic treatments will not be eligible. Participants can expect to receive the new treatment and to be closely monitored for its effects on their condition. This study could provide valuable information that may help improve the management of SLE in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old, not exceeding 70 years old (including 70 years old);
• • 2. Patients diagnosed with systemic lupus erythematosus (SLE) according to 2019 American College of Rheumatology/European League Against Rheumatism (2019ACR/EULAR) international classification diagnostic criteria;
• • 3. Accepting the treatment of telitacicept.
• Exclusion Criteria:
• Subjects who meet any of the following criteria should be excluded from this study:
• • 1. Patients with other rheumatic immune system diseases;
• • 2. Patients in the active stage of acute and chronic infections;
• • 3. Patients using other biologics;
• • 4. Patients with wasting diseases such as malignant tumors